Clinical trials
Autoimmune Encephalitis clinical trials
Below are recruiting autoimmune encephalitis clinical trials, each written for real people, not researchers. We’re tracking 26 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07707739Recruiting
Plasma exchange for children with autoimmune encephalitis
This trial tests whether plasma exchange (a procedure that cleans the blood) can help children with a severe form of autoimmune encephalitis—a condition where the immune system attacks the brain. It's for children who haven't gotten better with standard treatments like steroids or IVIG.
Shibīn al Kawm, Menoufia GovernorateAges 1 month–18 years - NCT03993262RecruitingPhase 2
Bortezomib for severe autoimmune encephalitis after rituximab
This Phase 2 study tests whether bortezomib can improve outcomes and safety in adults with severe autoimmune encephalitis. It focuses on people whose condition is confirmed by brain-related autoantibodies and who have already received rituximab.
München, BavariaAges 18 years+ - NCT05017142Recruiting
Pediatric brain inflammation registry for Swiss patients
This study is a registry that collects health information from children and teens in Switzerland diagnosed with certain inflammatory brain and spinal cord conditions. It helps researchers understand these illnesses better over time and may guide future treatments.
Aarau, Canton of AargauAges Up to 36 years - NCT06019975Recruiting
Using Brain PET Scans to Diagnose Autoimmune Encephalitis
This study uses a special brain scan (FDG-PET) to better understand autoimmune encephalitis, a condition where the immune system attacks the brain. It may help doctors improve diagnosis by comparing PET scan results with other tests you already had.
Udine, Friuli Venezia GiuliaAges Any age - NCT06584045Recruiting
Testing a bile-based treatment for adult encephalitis
This study tests a natural bile-derived medicine (Calcus Bovis Sativus) to see if it can help adults with new or recent brain inflammation (encephalitis). It focuses on people whose encephalitis is caused by the immune system or a virus, and who have not fully recovered.
Wuhan, HubeiAges 18 years+ - NCT07133113Recruiting
Effects of treatments in autoimmune encephalitis
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
BronAges Any age - NCT07477015Recruiting
Study to find new antibodies in autoimmune encephalitis
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
Rome, RMAges 18 years+ - NCT07488117RecruitingPhase 2
PET scan to detect brain inflammation in autoimmune encephalitis
This trial uses a special PET scan (with a tracer called [18F]-DPA-714) to see if it can measure inflammation in the brain caused by autoimmune encephalitis. The goal is to see if this scan can help doctors diagnose and monitor the condition more accurately.
ToulouseAges 18–80 - NCT06173076Recruiting
Study of outcomes in anti-LGI1 brain inflammation
This study follows people newly diagnosed with anti-LGI1 encephalitis (a brain inflammation) to see how well they do over time. It aims to learn more about the condition and improve care.
Hangzhou, ZhejiangAges 18–100 - NCT04372615RecruitingPhase 2
Inebilizumab for NMDA receptor encephalitis after initial steroids
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
Birmingham, AlabamaAges 12 years+ - NCT05772611Recruiting
Study of immune responses in brain autoimmune and nerve syndromes
This study looks at how the immune system works in certain neurological conditions, including autoimmune encephalitis and related nerve disorders. Researchers may use blood and/or spinal fluid samples, especially when antibodies are present or can’t be found, to better understand what’s driving the illness.
LyonAges 18 years+ - NCT06079294Recruiting
Autoimmune encephalitis and brain glucose metabolism
This study looks at how autoimmune encephalitis affects brain metabolism using a special PET scan. It aims to better understand the condition in people who were recently diagnosed.
ParisAges 18 years+ - NCT05198661Recruiting
Blood or spinal fluid study in autoimmune brain disorders
This study collects information from people with autoimmune encephalitis or related nerve/brain disorders, using blood and sometimes spinal fluid. It helps researchers better understand these conditions, which may guide future diagnosis and treatments.
Pointe à Pitre, GuadeloupeAges Any age - NCT07583641RecruitingPhase 2
Testing Efgartigimod for Autoimmune Brain Inflammation
This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.
Tucson, ArizonaAges 12 years+ - NCT07158229Recruiting
Long-term effects of NMDAR encephalitis
This study follows adults with NMDAR encephalitis over time to understand its long-term effects. It uses online questionnaires, so you need internet access at home.
BronAges 18 years+ - NCT06867991RecruitingPhase 3
Combination therapy for autoimmune encephalitis
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
Zhengzhou, HenanAges 12 years+ - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT06502015Recruiting
Biomarkers in nervous system autoimmune diseases
This study looks for biomarkers (biological clues) in people with autoimmune diseases of the nervous system. It aims to discover better ways to diagnose and treat these conditions.
WuhanAges 18 years+ - NCT07093333RecruitingPhase 2
Testing a new antibody treatment for anti-NMDAR brain disease
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
SeoulAges 18–65 - NCT06939166RecruitingEarly Phase 1
Immune cell therapy for relapsed neurological autoimmune diseases
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT07337785RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Wuhan, HubeiAges 18–70 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT04806620Recruiting
Online app study for brain inflammation lifestyle data
This study uses a digital platform (app/website) to collect lifestyle and symptom information to better understand brain inflammation. You may qualify if you have certain conditions like Long COVID, migraines, autoimmune disease, inflammatory gut issues, mood disorders, or if you are a healthy comparison person.
Delafield, WisconsinAges 2 years+ - NCT06388161Recruiting
Autoantibody study in new focal seizures
This research study looks for specific immune system markers (autoantibodies) in the blood and spinal fluid of people who have recently started having focal seizures (seizures that start in one part of the brain) with no known cause. Finding these markers could help doctors understand why the seizures started.
Hangzhou, ZhejiangAges 14–100
Hear when a new Autoimmune Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune encephalitis?
- Yes. Clin2 currently lists 26 recruiting autoimmune encephalitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune encephalitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune encephalitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.